Processa Pharmaceuticals, Inc. Other Non-Current Assets
Processa Pharmaceuticals, Inc. (PCSA) had Other Non-Current Assets of $5.54 thousand as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2024-03-29
- 2023-12-31: Other Assets, Noncurrent $5.54K.
- 2023-09-30: Other Assets, Noncurrent $172.57K.
- 2023-06-30: Other Assets, Noncurrent $193.14K.
- 2023-03-31: Other Assets, Noncurrent $213.32K.
| Period end | Other Assets, Noncurrent | Other Assets, Noncurrent as first filed |
|---|---|---|
| 2023-12-31 | $5.54K 10-K · filed 2024-03-29 | |
| 2023-09-30 | $172.57K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $193.14K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $213.32K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $5.54K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $7.72M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $7.70M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $7.92M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $5.54K 10-K · filed 2023-03-30 | $8.14M 10-K · filed 2022-03-30 |
| 2021-09-30 | $8.36M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $8.57M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $8.79M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $9.01M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $9.21M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $9.43M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $9.65M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $9.87M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $10.09M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $10.30M 10-Q · filed 2019-08-14 | |
| 2018-12-31 | $10.44M 10-K · filed 2020-03-06 | |
| 2018-09-30 | $10.64M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $10.82M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $11.02M 10-Q · filed 2018-05-21 | |
| 2017-12-31 | $5.54K 10-Q · filed 2018-11-14 | |
| 2016-12-31 | $5.54K 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |